- Home
- CRIS vs IMNN Comparison
CRIS vs IMNN Comparison
Compare CRIS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | IMNN |
|---|---|---|
| Founded | 2000 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 12.9M |
| IPO Year | 2000 | 1985 |
Fundamental Metrics
Financial Performance| Metric | CRIS | IMNN |
|---|---|---|
| Price | $1.33 | $3.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | ★ $182.61 |
| AVG Volume (30 Days) | ★ 109.2K | 33.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,650,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $1.02 | $3.56 |
| 52 Week High | $4.50 | $41.22 |
Technical Indicators
Market Signals| Indicator | CRIS | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 45.89 |
| Support Level | $1.29 | $3.83 |
| Resistance Level | $1.42 | $4.09 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 75.02 | 73.21 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).